March 7, 2011 / 3:12 PM / 7 years ago

US Supreme Court won't review drug patent deal

WASHINGTON, March 7 (Reuters) - The U.S. Supreme Court declined on Monday to review whether patent settlements by drug companies that pay rivals to delay production of generic drugs violate federal antitrust law.

The justices refused to review a U.S. appeals court ruling that upheld the dismissal of a legal challenge over Bayer AG (BAYGn.DE) paying Teva Pharmaceutical Industries Ltd’s (TEVA.TA) TEVA.O Barr Laboratories to prevent it from bringing to market a version of the antibiotic drug Cipro. (Reporting by James Vicini, Editing by Gerald E. McCormick)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below